AI rare disease patient finder market seen nearly tripling by 2030

The market for AI-powered rare disease patient finders is projected to jump from $1.62 billion in 2025 to $5.95 billion by 2030 as drugmakers and researchers push harder for faster trial recruitment and better patient matching. North America led in 2025, while Asia-Pacific is expected to grow the fastest.

Why it matters: - AI-powered patient finding tools can speed rare disease research by matching patients to clinical trials, studies and treatment options more efficiently. - Faster identification of eligible patients can shorten clinical trial recruitment timelines and improve enrollment in hard-to-recruit rare disease populations. - The market’s growth reflects broader demand for precision medicine, real-world evidence analytics and digital health infrastructure.

What happened: - The Business Research Company published a global market report on the AI-driven rare disease patient finder market, covering size, trends, forecasts and competitive dynamics through 2035. - The market is estimated at $1.62 billion in 2025 and projected to reach $2.11 billion in 2026. - The report projects the market will reach $5.95 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is forecast to be the fastest-growing region over the next several years.

The details: - AI-powered rare disease patient finders use algorithms to identify patients with rare diseases and connect them to relevant clinical trials, research studies and tailored treatments. - The systems analyze medical records, genetic profiles and real-world health data to improve patient matching. - Historical growth has been driven by more electronic health records, early use of data analytics in clinical research, larger genomic databases, greater attention to orphan diseases and initial AI use in trial recruitment. - The report expects growth to be supported by increased investment in precision medicine research and stronger partnerships between healthcare and life sciences companies. - The report also points to broader use of real-world evidence analytics, stronger regulatory support for rare disease innovation and rising demand for faster clinical trial enrollment. - Anticipated product and platform trends include AI-based patient identification algorithms, deeper integration of multi-source health data, more automation in trial recruitment and expansion of precision patient matching platforms. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.

Between the lines: - Digital health adoption is becoming a key tailwind because AI patient finders work best when connected to usable health data and remote-care workflows. - OECD data cited in the report showed online digital health services reached 82% availability in 2024 among countries with comparable data, up from 79% in 2023. - Expanded access to electronic health records is making it easier for researchers and providers to identify rare disease patients across fragmented datasets.

What's next: - The market is expected to keep expanding through 2030 as healthcare systems and life sciences companies invest more in data-driven patient identification. - The report signals further adoption of multi-source data integration and automated recruitment tools as rare disease research scales. - The Business Research Company is offering a free sample and the full report online: Free sample report and the full market report. - The report also lists company contact details for follow-up, including Saumya Sahay at marketing@tbrc.info.